Holen Sie sich die Stockscreener-App
6.71
0.30%
0.02
Handel nachbörslich:
6.71
Schlusskurs vom Vortag:
$6.69
Offen:
$6.62
24-Stunden-Volumen:
220.05K
Relative Volume:
3.25
Marktkapitalisierung:
$208.92M
Einnahmen:
-
Nettoeinkommen (Verlust:
$-69.00M
KGV:
-2.6851
EPS:
-2.499
Netto-Cashflow:
$-55.26M
1W Leistung:
-4.96%
1M Leistung:
+3.23%
6M Leistung:
+2.91%
1J Leistung:
+40.97%
1-Tages-Spanne:
$6.51
$7.18
1-Wochen-Bereich:
$6.51
$7.445
52-Wochen-Spanne:
$3.19
$11.90
Acrivon Therapeutics Inc Stock (ACRV) Company Profile
Firmenname
Acrivon Therapeutics Inc
Sektor
Branche
Telefon
617-207-8979
Adresse
480 ARSENAL WAY, SUITE 100, WATERTOWN
Vergleichen Sie ACRV mit anderen Aktien
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
ACRV
Acrivon Therapeutics Inc
|
6.71 | 208.92M | 0 | -69.00M | -55.26M | -2.78 |
|
VRTX
Vertex Pharmaceuticals Inc
|
397.27 | 102.31B | 10.63B | -479.80M | -1.35B | -1.99 |
|
REGN
Regeneron Pharmaceuticals Inc
|
701.85 | 77.13B | 13.85B | 4.65B | 3.32B | 40.41 |
|
ARGX
Argen X Se Adr
|
623.82 | 37.30B | 1.86B | -40.29M | -1.28B | -0.85 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
245.44 | 31.66B | 2.09B | -332.26M | 16.06M | -2.62 |
|
BNTX
Biontech Se Adr
|
113.08 | 27.11B | 3.30B | -501.07M | 1.03B | -2.1146 |
Acrivon Therapeutics Inc Stock (ACRV) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2024-09-16 | Hochstufung | Ladenburg Thalmann | Neutral → Buy |
| 2024-04-29 | Herabstufung | Ladenburg Thalmann | Buy → Neutral |
| 2024-03-01 | Eingeleitet | JMP Securities | Mkt Outperform |
| 2023-12-15 | Fortgesetzt | Jefferies | Buy |
| 2023-10-05 | Eingeleitet | Maxim Group | Buy |
| 2023-06-02 | Eingeleitet | Oppenheimer | Outperform |
| 2023-05-08 | Eingeleitet | BMO Capital Markets | Outperform |
| 2023-04-27 | Eingeleitet | Ladenburg Thalmann | Buy |
| 2023-04-20 | Eingeleitet | H.C. Wainwright | Buy |
| 2022-12-12 | Eingeleitet | Cowen | Outperform |
| 2022-12-12 | Eingeleitet | Jefferies | Buy |
| 2022-12-12 | Eingeleitet | Piper Sandler | Overweight |
Alle ansehen
Acrivon Therapeutics Inc Aktie (ACRV) Neueste Nachrichten
(ACRV) Long Term Investment Analysis - Stock Traders Daily
Acrivon Therapeutics' SWOT analysis: oncology innovator's stock faces pivotal phase - Investing.com
Acrivon Therapeutics: Endometrial Cancer Data Continues To Justify A Nascent Thesis - Seeking Alpha
Acrivon Therapeutics' SWOT analysis: oncology biotech stock's platform potential By Investing.com - Investing.com Nigeria
Acrivon Therapeutics' SWOT analysis: oncology biotech stock's platform potential - Investing.com India
(ACRV) Technical Data - Stock Traders Daily
Acrivon Therapeutics, Inc. (NASDAQ:ACRV) Receives Consensus Rating of "Buy" from Analysts - MarketBeat
HC Wainwright Issues Pessimistic Outlook for ACRV Earnings - MarketBeat
We're Not Very Worried About Acrivon Therapeutics' (NASDAQ:ACRV) Cash Burn Rate - Simply Wall St
Acrivon Therapeutics’ (ACRV) “Buy” Rating Reiterated at HC Wainwright - Defense World
BMO Capital Markets Cuts Acrivon Therapeutics (NASDAQ:ACRV) Price Target to $27.00 - Defense World
When (ACRV) Moves Investors should Listen - Stock Traders Daily
Acrivon Therapeutics Reports Promising Clinical Progress and Financial Results - TipRanks
Acrivon stock retains Outperform as BMO cuts target due to minor cash adjustments - Investing.com
Acrivon Therapeutics (NASDAQ:ACRV) Price Target Cut to $27.00 by Analysts at BMO Capital Markets - MarketBeat
Acrivon Therapeutics (NASDAQ:ACRV) Given Buy Rating at HC Wainwright - MarketBeat
Acrivon Therapeutics Reports Third Quarter 2024 Financial Results and Business Highlights - GlobeNewswire
Acrivon's Cancer Drug Shows 62.5% Response Rate; Reports $202.8M Cash Position | ACRV Stock News - StockTitan
Acrivon Therapeutics, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2024 - Marketscreener.com
Acrivon Therapeutics, Inc. (NASDAQ:ACRV) Receives $23.83 Average PT from Analysts - Defense World
Trend Tracker for (ACRV) - Stock Traders Daily
Acrivon Therapeutics, Inc. (NASDAQ:ACRV) Receives Average Recommendation of "Buy" from Brokerages - MarketBeat
Acrivon Therapeutics, Inc. (NASDAQ:ACRV) Short Interest Update - Defense World
Acrivon Therapeutics' SWOT analysis: promising oncology pipeline faces market hurdles - Investing.com Canada
Acrivon Therapeutics' SWOT analysis: promising oncology pipeline faces market hurdles By Investing.com - Investing.com South Africa
(ACRV) Pivots Trading Plans and Risk Controls - Stock Traders Daily
Promising Endometrial Cancer Trial Data Puts Acrivon In Focus - RTTNews
Biomea Fusion (NASDAQ:BMEA) & Acrivon Therapeutics (NASDAQ:ACRV) Financial Survey - Defense World
Acrivon Therapeutics to Present Data Demonstrating Deployment of its AP3 Platform for Streamlined Drug Discovery and Clinical Development at Two Scientific ConferencesHuman Proteome Organization World Congress and EORTC-NCI-AACR Symposiu - GlobeNewswire
Acrivon Therapeutics, Inc. (NASDAQ:ACRV) Sees Large Drop in Short Interest - MarketBeat
Acrivon Therapeutics Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4) - GlobeNewswire
(ACRV) Investment Analysis and Advice - Stock Traders Daily
Acrivon Therapeutics Launches Phase 1 Cancer Trial, Advances Oncology Pipeline - Yahoo Finance
Acrivon Therapeutics, Inc. (NASDAQ:ACRV) Receives Average Rating of "Buy" from Brokerages - MarketBeat
Acrivon commences Phase 1 trial for cancer drug ACR-2316 - Investing.com
Acrivon Therapeutics Announces Initial Patient Dosing in Phase 1 Trial of ACR-2316, a Novel WEE1/PKMYT1 Inhibitor Designed Using AP3 for Superior Single-Agent Activity - GlobeNewswire
Acrivon Therapeutics Announces Initial Patient Dosing in Phase 1 Trial of ACR-2316, a Novel - The Bakersfield Californian
Acrivon Therapeutics, Inc. Announces Initial Patient Dosing in Phase 1 Trial of ACR-2316, a Novel WEE1/PKMYT1 Inhibitor Designed Using AP3 for Superior Single-Agent Activity - Marketscreener.com
Acrivon Therapeutics, Inc. (NASDAQ:ACRV) Shares Bought by Marshall Wace LLP - MarketBeat
Perceptive Advisors LLC Acquires 2,353,000 Shares of Acrivon Therapeutics, Inc. (NASDAQ:ACRV) - MarketBeat
Short Interest in Acrivon Therapeutics, Inc. (NASDAQ:ACRV) Expands By 24.3% - MarketBeat
Wall Street SWOT: Acrivon Therapeutics stock shows promise amid oncology challenges - Investing.com
The Potential Rise in the Price of ACM Research Inc (ACMR) following insiders activity - Knox Daily
Nippon Shinyaku buys $15 million of Capricor Therapeutics stock - Investing.com
Capricor Therapeutics price target raised to $25 from $12 at Maxim - TipRanks
Capricor stock surges on pipeline update (NASDAQ:CAPR) - Seeking Alpha
DRW Securities LLC Invests $287,000 in Arch Capital Group Ltd. (NASDAQ:ACGL) - Defense World
Capricor Therapeutics Shares Rise in Premarket on Plans to File Application for Deramiocel - MarketWatch
You might want to take a look at ACM Research Inc (ACMR) now - SETE News
When the Price of (ACRV) Talks, People Listen - Stock Traders Daily
Capricor (CAPR) Surges 18.2%: Is This an Indication of Further Gains? - Yahoo Finance
Finanzdaten der Acrivon Therapeutics Inc-Aktie (ACRV)
Umsatz
Nettogewinn
Free Cashflow
ENV
Acrivon Therapeutics Inc-Aktie (ACRV) Insiderhandel
| Insiderhandel | Beziehung | Datum | Transaktion | Kosten | #Aktien | Wert ($) | #Aktien Gesamt |
|---|---|---|---|---|---|---|---|
| PERCEPTIVE ADVISORS LLC | 10% Owner |
Apr 11 '24 |
Buy |
8.50 |
2,353,000 |
20,000,500 |
5,360,858 |
2.88%
2.65%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):